fda bpc-157 warning unapproved peptide compounding Targets GLP-1 and Compounding, Advertising and 'Research Use Only' Labeling The FDA just put peptides

Description

This patient-centered philosophy fosters trust and promotes positive health outcomes

Jun 19, 2026 Beetroot for Menopause, Birth Control, and the Triad Menopause reduces eNOS activity by 50 percent, and oral contraceptives suppress nitric oxide further

Often a good fit Recovery from training, injury, or surgery is slower than it used to be Weight that resists diet and exercise, often with insulin resistance Persistent fatigue and reduced clarity despite adequate sleep Declining muscle tone, skin quality, or sleep depth with age Chronic inflammatory or gut-related complaints, already worked up A longevity-oriented patient optimizing measurable biomarkers Reasons we may decline Active malignancy several peptides influence angiogenesis and cell growth Pregnancy or breastfeeding safety not established Certain endocrine conditions, or medication interactions Autoimmune disease, for immune-modulating peptides specifically Competitive athletes subject to testing many peptides are WADA-prohibited An undiagnosed symptom that deserves a workup, not a peptide Cost depends on the peptide, dosing, and route of administration